JP2016534996A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534996A5
JP2016534996A5 JP2016523209A JP2016523209A JP2016534996A5 JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5 JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5
Authority
JP
Japan
Prior art keywords
patient
administration
antigen
binding fragment
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016523209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/060432 external-priority patent/WO2015057668A1/en
Publication of JP2016534996A publication Critical patent/JP2016534996A/ja
Publication of JP2016534996A5 publication Critical patent/JP2016534996A5/ja
Pending legal-status Critical Current

Links

JP2016523209A 2013-10-15 2014-10-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 Pending JP2016534996A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019132432A Division JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Publications (2)

Publication Number Publication Date
JP2016534996A JP2016534996A (ja) 2016-11-10
JP2016534996A5 true JP2016534996A5 (https=) 2017-11-16

Family

ID=52809872

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016523209A Pending JP2016534996A (ja) 2013-10-15 2014-10-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2019132432A Active JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2021068065A Pending JP2021107421A (ja) 2013-10-15 2021-04-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019132432A Active JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2021068065A Pending JP2021107421A (ja) 2013-10-15 2021-04-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Country Status (12)

Country Link
US (4) US20150104447A1 (https=)
EP (2) EP3485902A1 (https=)
JP (3) JP2016534996A (https=)
KR (1) KR20160061352A (https=)
CN (2) CN113230399A (https=)
AU (2) AU2014334563A1 (https=)
BR (1) BR112016008082A2 (https=)
CA (1) CA2925402A1 (https=)
MX (2) MX2016004329A (https=)
RU (1) RU2706729C2 (https=)
SG (2) SG10201807318RA (https=)
WO (1) WO2015057668A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
BR112022010934A2 (pt) * 2019-12-06 2022-11-29 Sanofi Biotechnology Métodos para tratar copd administrando um antagonista de il-33
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
HUE036885T2 (hu) * 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) * 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab

Similar Documents

Publication Publication Date Title
JP2016534996A5 (https=)
Thibodeaux et al. A review of dupilumab in the treatment of atopic diseases
Dahl et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study
Mukherjee et al. Anti-IL5 therapy for asthma and beyond
Wedzicha et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients
Fala Ofev (Nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis
ES2716906T3 (es) Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab
JP2016513640A5 (https=)
JP2016515124A5 (https=)
D'Urzo et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease
JP2018505882A5 (https=)
Mkorombindo et al. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Donohue et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD
JP2014513121A5 (https=)
JP2013525310A5 (https=)
JP2014520874A5 (https=)
Singh et al. Biological therapy in COPD management: current evidence, challenges and opportunities
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
Mathioudakis et al. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
Gulati et al. Bringing stability to the chronic obstructive pulmonary disease patient: clinical and pharmacological considerations for frequent exacerbators
Kelleher et al. Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults
RU2013126798A (ru) Комбинированная терапия дексаметазоном
JP2017514829A5 (https=)
Colice Emerging therapeutic options for asthma